Health Administration Act 1982

The legislation directly binds and empowers the Minister for Health, the Health Secretary, the Ministry of Health, the Health Administration Corporation, the NSW Health Foundation, and every “relevant health services organisation” defined in s 21B: local health districts, prescribed statutory health corporations, prescribed affiliated health organisations, and the Health Secretary in respect of ambulance and certain Chapter 10 services under the Health Services Act 1997.

Every approved quality-assurance committee (s 20E) and every serious adverse event review team or assessor appointed under Part 2A is subject to the confidentiality, evidentiary and immunity rules. Health practitioners (defined by cross-reference to the Health Practitioner Regulation National Law (NSW)) whose performance or impairment may be relevant to an incident are affected by the mandatory-notification obligations in s 21J and the prohibition on reviewer investigation of individual competence (s 21M(1)).

Patients, their families and carers may receive limited, de-identified information about incidents (s 21F(1)(d)) but are otherwise shielded by the non-disclosure rules. Private bodies, councils and individuals who provide or fund health services are indirectly affected through the Minister’s power to facilitate their involvement (s 8(2)(f)–(i)) and the Foundation’s grant-making capacity (s 17).

Employees of the NSW Health Service who support the Corporation (note to s 9(2A)) and members of the Medical Services Committee, subcommittees and other advisory bodies appointed under s 20 fall within the Act’s governance. Health-professional councils established under s 41B of the National Law have their accounts managed by the Corporation (s 13A). Researchers authorised under s 23 to conduct morbidity or mortality studies receive special evidentiary privileges.

Because the Act cross-references the Health Services Act 1997, the Private Health Facilities Act 2007 and the Public Health Act 2010, its practical reach extends to almost every public and many private health-service providers and regulators in New South Wales.

The Minister’s central duty is to formulate general health policies (s 5(1)) and may determine that any Ministerial function be exercised by the Corporation or through joint ventures (s 5A(1)). The Health Secretary must initiate surveys, plan services, promote research and education, and is subject to Ministerial direction except as to the content of recommendations or reports (s 8(3)).

Relevant health services organisations carry mandatory duties once an incident is reported: they must appoint assessors for a preliminary risk assessment if the incident is or may be a reportable incident or may indicate a serious systemic problem (s 21C(1)). If the assessment or the Health Secretary so requires, a serious adverse event review team must be appointed (s 21G(1)). The organisation must keep a written record of team members (s 21G(4)) and may direct preparation of a recommendations report after considering the initial findings (s 21H(3)).

Incident reviewers (assessors and team members) must act fairly and reasonably (s 21M(3)), must not investigate individual competence (s 21M(1)), and must immediately notify the organisation in writing of any imminent serious harm (ss 21E, 21I) or performance/impairment issues (s 21J). Reviewers are prohibited from recording or disclosing information except for statutory purposes or as permitted by regulation (s 21N).

Quality-assurance committees may assess services only if declared by Ministerial Gazette order after satisfaction of five statutory criteria (s 20E(2)). They must observe natural justice where relevant (s 20F(3)), must not disclose identities without consent (s 20F(2)), and their members enjoy qualified privilege in defamation and indemnity from the establishing organisation (s 20J).

The Corporation holds statutory rights to acquire and dispose of land (ss 10–11), accept gifts free of remoteness rules (s 12), and manage health-professional council accounts with investment powers under the Government Sector Finance Act 2018 (s 13A(4)). The Foundation may act as trustee and promote fundraising (s 17(4)).

Rights of review teams and assessors include protection from personal liability for good-faith acts (ss 20J, 21Q), evidentiary immunity (ss 20H, 21O–21P), and the ability to obtain additional members or discontinue reviews in defined circumstances (ss 21G(3A), 21K).

Patients and practitioners have the negative right that reviewer reports and advice are generally inadmissible (s 21P) and that identities will not be disclosed without consent (s 21M(2)), subject to the performance-notification carve-out in s 21J.

The Act creates two offence provisions carrying 50 penalty units. Section 20G prohibits a current or former quality-assurance committee member from recording, divulging or communicating information acquired as a member except for statutory functions or in accordance with regulations. Section 21N imposes the identical prohibition on current or former incident reviewers.

Section 22 creates a broader secrecy offence (10 penalty units or six months’ imprisonment) for unauthorised disclosure of information obtained in the administration of the Act or any other Act conferring functions on the Minister, Ministry, Health Secretary, Corporation or Foundation. Section 23(3) mirrors this penalty for unauthorised disclosure of morbidity or mortality research information.

Enforcement is by prosecution in the Local Court only (s 24). No specific investigative or audit powers are created in the Act itself; instead s 21S(g)–(h) contemplates regulations for notification to and information exchange with bodies exercising functions under Part 4 of the Private Health Facilities Act 2007.

Civil enforcement occurs indirectly through the Corporation’s capacity to sue and be sued (s 9(2)(c)) and through the contractual and property powers in ss 10–13. Ministerial approval is a statutory precondition to land dealings (ss 10(1), 11(1)) and certain declarations under s 18(4); breach would render the transaction ultra vires.

Indemnities and good-faith defences (ss 20J, 21Q, 25) operate as shields rather than penalties. The Act contains no civil penalty regime or infringement-notice scheme.

The Act is expressly designed to sit atop a web of health legislation. The definition of “health service” in s 4(1) mirrors language used in the Health Services Act 1997. “Local health district”, “statutory health corporation” and “affiliated health organisation” are all defined by cross-reference to that Act (ss 4(1), 21B). Part 2A applies only to incidents involving those organisations or ambulance services under Chapter 5A or Part 1A of Chapter 10 of the Health Services Act 1997 (s 21B).

The Corporation’s land-acquisition powers are expressly tied to the Land Acquisition (Just Terms Compensation) Act 1991 and the Public Works Act 1912 (s 10). Sections 10(3)–(6) modify the operation of the latter statute. Land-disposal powers in s 11 interact with Crown grant trusts and forfeiture rules.

Quality-assurance and incident-review confidentiality provisions overlay the Health Practitioner Regulation National Law (NSW). Section 21J requires notification to the relevant organisation of performance or impairment issues even without practitioner consent; that information may then be passed to the Health Care Complaints Commission or a National Board. The evidentiary immunity in s 21O(2)(b) permits disclosure to a person or body approved by the Health Secretary to audit reviews.

Account-management functions in s 13A expressly reference the Health Practitioner Regulation National Law (NSW), the Government Sector Employment Act 2013 and the Government Sector Finance Act 2018. Investment powers differ according to whether the Corporation is a GSF agency (s 13A(4)).

The specially privileged research authorisations in s 23 override aspects of the Coroners Act 2009 (ss 23(5)–(6)). The information-exchange gateway in s 23A authorises disclosure between officials exercising functions under the Assisted Reproductive Technology Act 2007, Health Care Complaints Act 1993, Poisons and Therapeutic Goods Act 1966, Private Health Facilities Act 2007, Public Health Act 2010 and any prescribed Act.

Delegation rules in s 21 are expressed to be additional to, and not in derogation of, any other statutory delegation power (s 21(11)). Transitional provisions in Schedule 2 preserve the effect of amendments made by the original cognate Acts.

The Act therefore functions as both a constitutive statute and a procedural overlay that modifies evidentiary and confidentiality rules across the entire health regulatory landscape.

The most significant structural change occurred in 2018 with the insertion of Part 2A (Health Legislation Amendment Act 2018 Sch 1[2]). Division 6C (the former root-cause-analysis provisions) was repealed and replaced by a two-stage model of preliminary risk assessment followed by serious adverse event review. The 2018 amendments extended the new Part to incidents occurring before commencement (cl 21 of Schedule 2) but preserved existing RCA teams under the old law (cl 22). The changes were designed to clarify triggers for review, strengthen immediate-notification obligations for imminent harm and practitioner issues, and rationalise evidentiary protections into a single set of provisions (ss 21O–21P) that apply to both assessors and review-team members.

Section 21G was further amended in 2023 (Health Legislation Amendment Act 2023 Sch 1[1]–[2]) to permit replacement of team members and additional appointments where necessary for timely completion, reflecting practical difficulties experienced with fixed teams.

Section 13A has been amended multiple times to update references to public-finance legislation (Government Sector Finance Act 2018, Government Sector Employment Act 2013) and to clarify the Corporation’s role as deemed employer for council staff costs.

The 2010 amendments (Health Legislation Amendment Act 2010) refined RCA reporting obligations and extended evidentiary immunity to documents prepared before the amendments, responding to early litigation uncertainty about the scope of protection.

The overall legislative trajectory shows a move from pure administrative restructuring in 1982 toward a modern clinical-governance statute that privileges systemic learning, immediate risk mitigation and controlled information flow between regulators.

The source text itself does not record specific court decisions. However, the structure of the quality-assurance and incident-review provisions reveals the legislative response to recurring tensions. Sections 20H, 20I, 21O and 21P create absolute or near-absolute evidentiary shields. The policy choice to render reviewer advice and reports inadmissible (s 21P(1)) even in coronial or civil proceedings (subject only to proceedings against the reviewer) has attracted criticism from plaintiff lawyers who argue it reduces transparency and accountability. Conversely, health-sector stakeholders maintain that without these protections candid discussion of adverse events would cease, undermining the very purpose of the legislation.

The distinction drawn in s 21J between mandatory notification for professional misconduct, unsatisfactory professional conduct or impairment, and discretionary notification for unsatisfactory professional performance, reflects a compromise between protecting the public and preserving the review’s non-punitive character. The prohibition on investigating individual competence (ss 20F(1), 21M(1)) is designed to prevent “dual purpose” reviews that could later be challenged as disciplinary inquiries in disguise.

Section 23’s override of certain coronial powers in anaesthetic-death cases has been controversial in the past because it limits the coroner’s access to morbidity-research data even when a death is reportable. The provision was retained when the Coroners Act 2009 replaced the 1980 Act, indicating continued legislative preference for research confidentiality.

No textual indication is given of constitutional challenges; the Corporation’s status as a statutory body representing the Crown (s 9(2)(f)) and the Minister’s ability to exercise functions through the Corporation (s 5A) have been drafted to avoid Executive/Crown separation arguments.

Most practitioners assume that once a serious adverse event review is commenced it must run to completion and produce recommendations. Section 21K permits the organisation to authorise discontinuation where the review team has identified a performance or impairment issue that substantially caused the incident and no other root causes are likely. The reviewer may then simply stop; many organisations fail to document the authorisation, exposing the process to later challenge.

The identity non-disclosure rule in s 21M(2) is qualified by “as far as is practicable”. Organisations sometimes over-redact, rendering reports useless, or under-redact, breaching the section. The obligation is to take reasonable steps when giving information to patients or carers under s 21F(1)(d); “reasonable steps” is not defined and has not been the subject of regulatory guidance in the Act.

Section 21J(1) requires written advice “as soon as practicable” once the team forms the opinion that a performance or impairment issue (other than unsatisfactory professional performance) “may” exist. The threshold is low; waiting for certainty can breach the duty. Conversely, notifying too early without sufficient material risks defamation claims, yet the qualified privilege in s 21Q(2) is available only if the statement is made in the exercise of reviewer functions.

The Corporation’s inability to employ staff (s 9(2A)) is often overlooked when drafting service contracts; any staff supporting the Corporation must be NSW Health Service employees whose costs may be charged to council accounts under s 13A(3).

Schedule 2 cl 21 provides that Part 2A applies to pre-commencement incidents. Organisations have inadvertently destroyed contemporaneous RCA documentation believing the old evidentiary regime no longer applied, only to discover the new protections still attach.

Finally, the “dominant purpose” test in s 21O(1) for evidentiary immunity is narrower than the “sole purpose” test that appeared in earlier versions of root-cause-analysis legislation. Documents prepared for multiple purposes may fall outside protection even if one purpose was review.

Compliance begins with robust incident-reporting policies that define when an incident is “reported” to the chief executive or nominated officer (s 21R). Organisations should maintain a register that records the precise time and person to whom every potentially reportable incident is notified.

A standing panel of suitable assessors should be pre-appointed so that a preliminary risk assessment can commence within hours (s 21C). Assessors must be chosen for objectivity and expertise; using staff directly involved in the incident risks breaching the “reasonably considers can properly carry out” test in s 21C(3).

Organisations must have a written procedure for deciding whether to convene a serious adverse event review team after receiving assessor advice. The decision must be documented, particularly where the Health Secretary has directed a review. Team members should sign conflict-of-interest declarations; the power to replace or add members (s 21G(3A)) should be exercised promptly when workload or expertise gaps appear.

All review-team communications must be marked “Prepared for the dominant purpose of a serious adverse event review under the Health Administration Act 1982” to maximise s 21O protection. Separate clinical records must be kept; reviewers must not annotate original medical records.

When a performance or impairment issue is identified, the exact wording of s 21J(3) must be followed: the written advice must disclose the practitioner’s identity, the nature of the concern, and the specific category (professional misconduct, unsatisfactory professional conduct, unsatisfactory professional performance or impairment). Failure to categorise correctly can invalidate subsequent regulatory action.

Organisations should maintain a central secure repository for all reviewer advice and reports. Access should be logged. Disclosure outside the permitted categories in s 21F(1) or s 21N risks both the 50-penalty-unit offence and loss of privilege.

Quality-assurance committees must be declared by Gazette order after the Minister is satisfied of the five criteria in s 20E(2). Terms of reference must expressly exclude individual competence investigations (s 20F(1)). Minutes must record that natural justice was afforded where relevant.

Annual training for all incident reviewers on the exact limits of s 21N is advisable. Contracts with external experts appointed to review teams should contain indemnity and confidentiality clauses mirroring the statutory protections.

Finally, legal sign-off should be obtained before any proposed disclosure to a law-enforcement agency, regulatory body or coroner. The interaction with s 23 research authorisations and coronial non-compellability must be checked in every death-related review.

By embedding these operational controls, organisations convert the Act’s complex protective architecture into a practical clinical-governance system that satisfies both the letter and the policy intent of the legislation.